First day of trading for Oncology Venture Sweden AB at the AktieTorget

Today July 22nd 2015 is the first day of trading for Oncology Venture Sweden AB (”Oncology Venture”) at the AktieTorget.

Trading at the AktieTorget
Today is the first day of trading for Oncology Ventures Sweden at the AktieTorget. The share code is OV (OV.ST) and the ISIN code is SE0007157409.

For more information, please contact:
Peter Buhl Jensen, CEO
Phone: +45 21 60 89 22
E-mail: pbj@buhloncology.com

About Oncology Venture Sweden AB
Oncology Venture Sweden AB runs cancer drug development through the fully owned Danish daughter company Oncology Venture ApS. Oncology Venture has license to use Drug Response Prediction – DRPTM – to significantly increase the likelihood of success in clinical trials. Oncology Venture aims to rescue cancer drugs, which has previously stopped in clinical development. DRPTM has shown its ability to provide statistically significant prediction of clinical trial results with an anti-cancer treatment in patients in 26 out of 32 tested clinical studies.

Oncology Venture works with a model that changes the odds compared to traditional drug development. Instead of treating all patents with the same cancer disease patients will be screened beforehand and only patients who have a likelihood of responding to the anti-cancer drug will then be treated. Having a better defined patient population risk, cost will be reduced, and the development process will be more efficient.